Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05811364

The GORE VBX FORWARD Clinical Study: A Comparison of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis to Bare Metal Stenting for Patients With Complex Iliac Occlusive Disease

The objective of this prospective, multicenter, randomized, controlled clinical trial is to demonstrate the superiority of the VBX Device for primary patency when compared to bare metal stenting in complex iliac occlusive disease.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Central Adelaide Local Health Network Incorporated, Adelaide, Australia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years at time of informed consent signature
  • Informed Consent Form (ICF) is signed by the subject
  • Subject can comply with protocol requirements, including follow-up
  • Patient has symptomatic claudication, rest pain, or minor tissue loss (Rutherford Category 2-5)
  • Patient has de novo or restenotic lesion(s) found in the common and/or external iliac artery(ies)
  • Patient has: Unilateral or bilateral single or multiple lesions (>50% stenosis or chronic total occlusion) each between 4 and 11 cm in length
  • Patient has a target vessel diameter visually estimated to be approximately between 5 mm and 13 mm
  • Patient has a sufficient (<50% stenotic) common femoral artery and at least one sufficient (<50% stenotic) femoral artery (deep or superficial).
  • Patient has at least one sufficient (<50% stenotic) infrapopliteal run-off vessel.

Exclusion criteria

  • Life expectancy <1 year
  • Patient is pregnant at time of informed consent.
  • Patient has a known allergy to stent or stent graft components (including nitinol, stainless steel, or heparin).
  • Patient has severe chronic renal insufficiency (serum creatinine level > 2.5mg/dL) and not undergoing hemodialysis.
  • Patient has evidence of a systemic infection.
  • Patient has a known intolerance to antithrombotic medications that prevent compliance with study or control device Instructions for Use.
  • Patient has had vascular catheterization of the lower extremities within 30 days of randomization (excluding diagnostic angiograms for the study procedure).
  • Patient has previous stenting in the iliac arteries.
  • Patient has previous surgical bypass in the target limb.
  • Patient is currently participating in another investigative clinical study unless received written approval by the sponsor.
  • Patient has a lesion requiring drug-coated balloon angioplasty, atherectomy, lithotripsy, or any ablative device to facilitate stent delivery.
  • Patient has an abdominal aortic artery lesion or aneurysm.
  • Patient has a lesion that requires stent placement within 2 cm of the inguinal ligament.
  • Patient has isolated common iliac artery stenosis that can be treated with a single device (i.e., common iliac artery stenosis that does not require kissing stents or extend into the external iliac artery).
  • Patient has outflow disease that requires concomitant interventions (i.e. common femoral endarterectomy or femoral / tibial revascularization).

Treatment and study plan

Stenting of the Common and/or External Iliac Arteries with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis

Device

Treatment of target lesions in the common and/or external iliac arteries by stenting with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis.

Stenting of the Common and/or External Iliac Arteries with Bare Metal Stent

Device

Treatment of target lesions in the common and/or external iliac arteries by stenting with a commercially available bare metal stent that is approved for treatment of the disease.

Primary outcomes

  1. Primary Patency

    Time frame: 1 year

    Blood flow through the target lesion (no evidence of binary restenosis >50% or occlusion) without a Target Lesion Revascularization (TLR).

Secondary outcomes

  1. Technical success

    Time frame: at the procedure

    Deployment of device with < 30% residual stenosis on final angiography.

  2. Acute procedural success

    Time frame: at the procedure

    Binary assessment based on technical success and freedom from device or procedure-related serious adverse events (SAE) requiring intervention.

  3. Clinical success

    Time frame: Through 1 month

    Improvement from baseline of at least 1 Rutherford Category and freedom from device or procedure-related SAE requiring intervention.

  4. Hemodynamic Status

    Time frame: Through 5 years

    Change in Ankle-brachial index (ABI)/toe-brachial index (TBI) as compared to baseline

  5. Change in EQ-5D-5L

    Time frame: Through 5 years

    Change in EQ-5D-5L responses as compared to baseline. The EQ-5D-5L Questionnaire measures quality of life (QoL) over 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is measured over five levels from no problems to extreme problems. Scored on a 0 to 100 scale with 0 as the worst possible health and 100 is the best possible health.

  6. Change in WIQ

    Time frame: Through 5 years

    Change in Walking Impairment Questionnaire (WIQ) responses as compared to baseline. The WIQ is a validated QoL measurement of walking abilities over 3 dimensions: distance, speed, and stair-climbing. Scored on a 0 to 100 scale with 0 as no degree of difficulty and 100 is the highest degree of difficulty.

  7. Primary patency

    Time frame: Through 5 years

    Blood flow through the target lesion (no evidence of binary restenosis >50% or occlusion) without a Target Lesion Revascularization (TLR).

  8. Freedom from binary restenosis

    Time frame: Through 5 years

    Freedom from binary restenosis. binary restenosis defined as evidence of >50% restenosis or occlusion of the target lesion(s) based on core lab adjudicated duplex ultrasound or angiography

  9. Primary assisted patency

    Time frame: Through 5 years

    Blood flow maintained (no evidence of occlusion) through the target lesion with or without a Target Lesion Revascularization (TLR).

  10. Secondary patency

    Time frame: Through 5 years

    Blood flow through the target lesion with or without a Target Lesion Revascularization (TLR).

  11. Freedom from target lesion revascularization

    Time frame: Through 5 years

    Freedom from target lesion revascularization (TLR). TLR defined as endovascular or surgical intervention performed on the target lesion(s).

  12. Cumulative reintervention rate

    Time frame: Through 5 years

    Rate of first and recurrent Target Lesion Revascularization (TLR).

  13. Freedom from clinically driven target lesion revascularization

    Time frame: Through 5 years

    Freedom from clinically driven target lesion revascularization. Endovascular or surgical intervention performed on the target lesion(s) in response to recurrent symptoms (increase ≥ 1 Rutherford Category).

  14. Amputation-free survival

    Time frame: Through 5 years

    Binary assessment based on freedom from major amputation (target limb, amputation above the metatarsals) and all-cause mortality

  15. Survival

    Time frame: Through 5 years

    Freedom from all-cause mortality

  16. Change in Rutherford Category

    Time frame: Through 5 years

    Change in Rutherford Category as compared to baseline. Scaled from 0 to 6, with 0 as asymptotic and 6 as major tissue loss, extending above the transmetatarsal (TM) level, functional foot no longer salvageable.

Study contacts

Contact information is provided by the study sponsor or research team.

Alexander Ambrocik

CONTACT

[email protected]

337-387-4954

Enoque Costa

CONTACT

[email protected]

928-525-4044

Sponsors and collaborators

Lead sponsor

W.L.Gore & Associates

Industry

Registry information

Important dates

Study start
2023
Primary completion
2028
Study completion
2032
First posted
Apr 13, 2023
Registry last updated
May 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.